文献速递前列腺癌

VISION:比较磁共振靶向活检与标准经直肠超声引导活检检测前列腺癌的随机试验个体患者数据荟萃分析

VISION: An Individual Patient Data Meta-analysis of Randomised Trials Comparing Magnetic Resonance Imaging Targeted Biopsy with Standard Transrectal Ultrasound Guided Biopsy in the Detection of Prostate Cancer.
PubMed 文献 · Eur Urol · 2024-09-03

VISION是一项预先计划的个体患者数据荟萃分析,比较MRI±靶向活检与标准经直肠超声引导活检对临床显著性前列腺癌(csPCa)的检出。纳入PRECISION和PRECISE两项随机试验共953例活检初治患者。MRI±靶向活检路径检出csPCa比TRUS活检多8.7个百分点,检出临床非显著性前列腺癌(cisPCa)少12.3个百分点。

要点

  • MRI±靶向活检组中32.2%患者因MRI无可疑病灶而避免活检。
  • MRI±靶向活检检出csPCa为36.3%,TRUS活检为27.6%,差异8.7个百分点(95%CI 2.8-14.6,p=0.004)。
  • MRI±靶向活检检出cisPCa为9.6%,TRUS活检为21.9%,差异12.3个百分点(95%CI 7.8-16.9,p<0.001)。

核心结论

  • MRI±靶向活检路径在检出csPCa和避免cisPCa诊断方面优于TRUS活检。
  • MRI应纳入前列腺癌诊断的标准诊疗路径。

研究设计与样本

  • 个体患者数据荟萃分析(IPDMA),检索MEDLINE、EMBASE、Web of Science、Cochrane Central of Registered Trials和ClinicalTrials.gov(检索日期2023年11月12日)。
  • 纳入活检初治、临床怀疑前列腺癌并接受MRI或标准TRUS的随机对照试验,要求MRI可疑者仅接受靶向活检、MRI不可疑者避免活检。
  • 纳入PRECISION和PRECISE两项研究,共953例患者。

主要发现

  • MRI±靶向活检组中32.2%患者因MRI无可疑病灶而避免活检。
  • MRI±靶向活检检出csPCa为36.3%,TRUS活检为27.6%,差异8.7个百分点(95%CI 2.8-14.6,p=0.004)。
  • MRI±靶向活检检出cisPCa为9.6%,TRUS活检为21.9%,差异12.3个百分点(95%CI 7.8-16.9,p<0.001)。
  • 使用QUADAS-2、QUADAS-C和ROB 2.0工具评估,纳入研究的总体偏倚风险为低。

关键数值与推荐

  • 主要结局为诊断为csPCa(Gleason≥3+4)的男性比例。
  • cisPCa定义为Gleason 3+3。

临床怎么用

  • MRI应纳入前列腺癌诊断的标准诊疗路径。

局限性

  • 仅纳入两项研究(PRECISION和PRECISE),共953例患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: The PRECISION and PRECISE trials compared magnetic resonance imaging targeted biopsy (MRI ± TB) with the standard transrectal ultrasound (TRUS) guided biopsy for the detection of clinically significant prostate cancer (csPCa). PRECISION demonstrated superiority of MRI ± TB over TRUS guided biopsy, while PRECISE demonstrated noninferiority. The VISION study is a planned individual patient data meta-analysis (IPDMA) comparing MRI ± TB with TRUS guided biopsy for csPCa diagnosis. METHODS: MEDLINE, EMBASE, Web of Science, Cochrane Central of Registered Trials, and ClinicalTrials.gov were searched on the November 12, 2023 for randomised controlled trials of biopsy-naïve patients with a clinical suspicion of prostate cancer undergoing MRI or standard TRUS. Studies were included if its participants with suspicious MRI underwent targeted biopsy alone and those with nonsuspicious lesion avoided biopsy. The primary outcome is the proportion of men diagnosed with csPCa (Gleason ≥3 + 4). KEY FINDINGS AND LIMITATIONS: Two studies, PRECISION and PRECISE (953 patients), were included in the IPDMA. In the MRI ± TB arm, 32.2% of patients avoided biopsy due to nonsuspicious MRI. MRI ± TB detected 8.7 percentage points (36.3% vs 27.6%; 95% confidence interval [CI] 2.8-14.6, p = 0.004) more csPCa than TRUS biopsy and 12.3 percentage points (9.6% vs 21.9%; 95% CI 7.8-16.9, p < 0.001) less clinically insignificant prostate cancer (cisPCa; Gleason 3 + 3). The overall risk of bias for the included studies were found to be low after assessment using the QUADAS-2, QUADAS-C, and ROB 2.0 tools. CONCLUSIONS AND CLINICAL IMPLICATIONS: The MRI ± TB pathway is superior to TRUS biopsy in detecting csPCa and avoiding the diagnosis of cisPCa. MRI should be included in the standard of care pathway for prostate cancer diagnosis.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Kasivisvanathan V, Wai-Shun Chan V, Clement KD, et al. VISION: An Individual Patient Data Meta-analysis of Randomised Trials Comparing Magnetic Resonance Imaging Targeted Biopsy with Standard Transrectal Ultrasound Guided Biopsy in the Detection of Prostate Cancer. Eur Urol. 2024. PMID: 39232979. doi:10.1016/j.eururo.2024.08.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。